Our Partners

At OPKO Health, the entrepreneurial acumen of founder and CEO, Dr. Phillip Frost, has led to the development of a diverse healthcare company flexible enough to adapt to evolving patient needs. Their first in class products include, Rayaldee® (calcifediol), and the 4Kscore® test, as well as their diagnostics division, BioReference Laboratories and GeneDx. In addition to their clinical products and diagnostics, they have a robust research and development pipeline and a variety of biomedical and pharmaceutical business solutions.

Aqualung is an early-stage biotech company developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung and systemic inflammation. Founded in 2016 and led by a physician scientist, Aqualung’s science-driven approaches led them to the identification of nicotinamide phosphoribosyltransferase (NAMPT) as a contributor to severe inflammatory diseases. Aqualung Therapeutics is developing eNamptor™, a Next Gen platform comprised of, i) ALT 100 mAb, a humanized eNAMPT-neutralizing monoclonal antibody; ii) eNAMPT-Plex, a plasma-based biomarker panel comprised of cytokines, including eNAMPT, which predicts ARDS mortality; and iii) NAMPT-Gene, a genotyping assay that identifies individuals at increased risk for ARDS death. The pipeline of ALT is designed to target a range of diseases, including ARDS, ventilator- and radiation-induced lung injury, chorioamnionitis, prostate cancer, pulmonary hypertension, and both pulmonary and hepatic fibrosis (NASH), conditions each with significant unmet medical needs and with significant morbidity and mortality. For additional information about the company, please visit www.aqualungtherapeutics.com.